ERBB2 and cancer: We here engrafted the additional specificity to the CD19scFv-CAR T cells by adding a composite protein consisting of the herceptin derived anti-ErbB2 4D5scFv domain for the cancer cell targeting and of the CD19 ectodomain, to allow the engagement by the anti-CD19 CAR.